Literature DB >> 3386521

In vivo determination of T1 and T2 in the brain of patients with severe but stable multiple sclerosis.

H B Larsson1, J Frederiksen, L Kjaer, O Henriksen, J Olesen.   

Abstract

In vivo measurements of relaxation processes in multiple sclerosis (MS) lesions by magnetic resonance imaging (MRI) may be important for evaluation of the disease activity in individual MS plaques. To obtain information of presumably chronic plaques, 10 patients with severe, but stable MS were investigated, using a whole-body superconductive MR scanner, operating at 1.5 T. By employing 12-point (or 6-point) partial saturation inversion recovery (PSIR) and 32-echo multiple spin-echo sequences we measured T1 and T2 in MS plaques, white matter, and cortical gray matter. We also focused on the issue, whether T1 and T2 relaxation processes in fact were monoexponential. T1 and T2 in plaques were found to cover a wide range, which could be explained only by inherent biophysical dissimilarity of the plaques, possibly due to differences in disease activity, edema and gliosis. T1 appeared monoexponential in all the plaques, but in seven cases T2 showed biexponential behavior. This was found to be most pronounced near the cerebrospinal fluid of the ventricles, probably caused by partial volume effects or increased free water content. The T2 of apparently normal white matter was significantly longer in MS patients than in healthy subjects.

Entities:  

Mesh:

Year:  1988        PMID: 3386521     DOI: 10.1002/mrm.1910070106

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  23 in total

Review 1.  Physicians, subsequence and consequence.

Authors:  W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Towards quantitative measurements of relaxation times and other parameters in the brain.

Authors:  P S Tofts; E P du Boulay
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

3.  Brain imaging with synthetic MR in children: clinical quality assessment.

Authors:  Aaron M Betts; James L Leach; Blaise V Jones; Bin Zhang; Suraj Serai
Journal:  Neuroradiology       Date:  2016-07-20       Impact factor: 2.804

Review 4.  Magnetic resonance imaging of myelin.

Authors:  Cornelia Laule; Irene M Vavasour; Shannon H Kolind; David K B Li; Tony L Traboulsee; G R Wayne Moore; Alex L MacKay
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

5.  Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.

Authors:  D H Miller; F Barkhof; I Berry; L Kappos; G Scotti; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-08       Impact factor: 10.154

6.  Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone.

Authors:  J Kesselring; D H Miller; D G MacManus; G Johnson; N M Milligan; N Scolding; D A Compston; W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

7.  Optimizing MR Scan Design for Model-Based ${T}_{1}$ , ${T}_{2}$ Estimation From Steady-State Sequences.

Authors:  Gopal Nataraj; Jon-Fredrik Nielsen; Jeffrey A Fessler
Journal:  IEEE Trans Med Imaging       Date:  2016-10-04       Impact factor: 10.048

8.  The dynamics of multiple sclerosis. The Charcot Lecture.

Authors:  W I McDonald
Journal:  J Neurol       Date:  1993-01       Impact factor: 4.849

9.  Changes within the "normal" cerebral white matter of multiple sclerosis patients during acute attacks and during high-dose cortisone therapy assessed by means of quantitative MRI.

Authors:  M Brainin; A Neuhold; T Reisner; E Maida; S Lang; L Deecke
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-12       Impact factor: 10.154

10.  Benign and secondary progressive multiple sclerosis: a preliminary quantitative MRI study.

Authors:  M Filippi; G J Barker; M A Horsfield; P R Sacares; D G MacManus; A J Thompson; P S Tofts; W I McDonald; D H Miller
Journal:  J Neurol       Date:  1994-02       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.